In September 2012 HistoRx was acquired by Genoptix®, a Novartis company: Genoptix having itself been an SBIR Involved firm before being acquired by Novartis in 2010. HistoRx offers advanced histopathology analysis platform, using the companys proprietary AQUA® technology capable of measuring biomarker concentration with sub-cellular resolution in tissue sections. HistoRx services are used throughout basic biomedical research, preclinical and clinical drug development studies, facilitating the efforts of pharmaceutical and biotechnology companies to improve efficiency and effectiveness throughout drug development to bring new targeted therapies to the market. HistoRx pursues internal programs to develop proprietary standard-of-care diagnostics that offer substantial improvements over existing immunohistochemistry-based tests. HistoRx provides academic researchers at leading institutions access to AQUA® technology for use exclusively in noncommercial research
